Last reviewed · How we verify
ARK-E021 10%
At a glance
| Generic name | ARK-E021 10% |
|---|---|
| Also known as | Not yet marketed |
| Sponsor | M. Arkin 1999 Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARK-E021 10% CI brief — competitive landscape report
- ARK-E021 10% updates RSS · CI watch RSS
- M. Arkin 1999 Ltd. portfolio CI